cfpac 1  (ATCC)

Journal: Cancer Diagnosis & Prognosis

Article Title: Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer

doi: 10.21873/cdp.10560

Figure Lengend Snippet: Verification of protein tyrosine phosphatase kappa (PTPRK) knockdown in pancreatic cancer cell lines. (A) QPCR results show the PTPRK expression in control cell line PANC-1 pEF and PTPRK knockdown cell line PANC-1 PTPRK kd . (B) PTPRK expression in CFPAC-1 pEF and CFPAC-1 PTPRK kd cell lines. (C) Western blot results show the PTPRK protein expression in both PANC-1 and CFPAC-1 cell lines with PTPRK nockdown. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: Human pancreatic cancer cell lines PANC-1 and CFPAC-1 were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

Techniques: Knockdown, Expressing, Control, Western Blot

Journal: Cancer Diagnosis & Prognosis

Article Title: Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer

doi: 10.21873/cdp.10560

Figure Lengend Snippet: Protein tyrosine phosphatase kappa (PTPRK) and cell proliferation. (A, B) A proliferation was performed to examine whether PTPRK is associated with pancreatic cell proliferation. (C, D) QPCR results show the expression of CDK6 and CCND1 in control cell lines PANC-1 pEF /CFPAC-1 pEF and PTPRK knockdown cell lines PANC-1 PTPRK kd /CFPAC-1 PTPRK kd . (E) TCGA dataset is used to draw a scatter plot showing the association between CDK6 and PTPRK at transcripts level. (F) In the TCGA dataset, the association between CCND1 and PTPRK transcript levels is shown. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: Human pancreatic cancer cell lines PANC-1 and CFPAC-1 were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

Techniques: Expressing, Control, Knockdown

Journal: Cancer Diagnosis & Prognosis

Article Title: Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer

doi: 10.21873/cdp.10560

Figure Lengend Snippet: Response to cyclin-dependent kinase 6 (CDK6) inhibitors in the protein tyrosine phosphatase kappa (PTPRK) knockdown pancreatic cancer cell line models. Both CFPAC-1 and PANC-1 cell lines were treated with different concentration of the CDK6 inhibitor BSJ-03-123 (A and B), CDK4/6 inhibitor Palbociclib (C and D) and CDK4 inhibitor 3-ATA (E and F). Corresponding IC 50 test results are shown. Cell viability was determined following a 3-day treatment with the inhibitors. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: Human pancreatic cancer cell lines PANC-1 and CFPAC-1 were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

Techniques: Knockdown, Concentration Assay

Journal: Cancer Diagnosis & Prognosis

Article Title: Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer

doi: 10.21873/cdp.10560

Figure Lengend Snippet: Protein tyrosine phosphatase kappa (PTPRK) and lymph node metastasis. (A) The scatter plot shows that the lymph angiogenesis marker VEGFC is inversely correlated with PTPRK in the TCGA cohort. QPCR shows the expression of VEGFC in pancreatic cancer cell lines PANC-1 (B) and CFPAC-1 (C) with PTPRK knockdown. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: Human pancreatic cancer cell lines PANC-1 and CFPAC-1 were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

Techniques: Marker, Expressing, Knockdown

Journal: bioRxiv

Article Title: Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function

doi: 10.64898/2026.04.13.717612

Figure Lengend Snippet: a, Intracellular cytokine staining of each Vδ2 T cell product with or without antigen stimulation with NALM6 for 4 hrs. SPICE plots showing the expression of individual cytokines (left) and bar graph summarizing the frequency of cells secreting different number of cytokines in multiple donors (mean ± S.E. n=5). b, c , Cytokine secretion from each Vδ2 T cell product in the supernatant without stimulation (b) and with stimulation (c) for 24 hrs (mean ± S.E. n=6). d-f, Results of 9-day coculture experiments against NALM6. Representative flow plots of coculture experiments from 10 independent experiments (d) . Line graphs showing target cell fold change (e) and CAR(+) cell fold change (f), and bar graphs showing Net area (baseline = 1) from day 0 to day 9 for each mean ± S.E. n=10). Statistical significance is calculated by a one-way ANOVA with Tukey’s multiple comparison (a, b, c, e, f). ✱ p ≤ 0.05, ✱✱ p ≤ 0.01, ✱✱✱ p ≤ 0.001, ✱✱✱✱ p ≤ 0.0001.

Article Snippet: 293T (human embryonic kidney cell line), NALM6 (pre-B-ALL cell line), CFPAC-1 (pancreatic ductal adenocarcinoma), CCRF-CEM (T-ALL) were obtained from the American Type Culture Collection (Rockville, MD), and BV173 (B-cell precursor leukemia) from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig, Germany).

Techniques: Staining, Expressing, Comparison

Journal: bioRxiv

Article Title: Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function

doi: 10.64898/2026.04.13.717612

Figure Lengend Snippet: a, Representative histogram of Fas expression on ex vivo expanded Vδ2 T cells. b, Representative overlay histograms of Fas ligand expression on Vδ2 T cells with or without antigen stimulation for 24 hrs. c, Schematic of ΔFas expression and expected downstream events. d, Schematic of γ-retroviral vector encoding ΔFas. e, Representative overlay histogram of surface Fas expression in transduced (NGFR+) and untransduced (NGFR-) population in ΔFas-modified Vδ2 T cells. f, Bar graph showing % apoptotic cells (Annexin V+ cells) upon exposure to soluble Fas ligand for 24 hrs (mean ± S.E. n=3). g, Results of 9-day coculture experiments against NALM6. Line graphs showing target cell fold change (left), CAR(+) cell fold change (middle) and % NGFR(+) cells (right) over time, and bar graphs showing Net area (baseline = 1) of tumor fold change (left) and CAR(+) fold change (right) from day 0 to day 9 (mean ± S.E. n=5). h-k, Results from in vivo experiments in NALM6 xenograft mouse model (n=6/group). h, Tumor progression in individual mice over time detected by CBG bioluminescence. i, AUC of tumor bioluminescence from day 0 to day 21 post Vδ2 T cell treatment. j, Vδ2 T cell expansion in individual mice over time detected by AkaLuc bioluminescence. k, Overall animal survival in each experimental group. Statistical significance is calculated by a two-way ANOVA with Sidak’s multiple comparison (f), Paired t test (g), Unpaired t test (i), or the log-rank test (k). ✱ p ≤ 0.05, ✱✱ p ≤ 0.01, ✱✱✱ p ≤ 0.001, ns; non-significant.

Article Snippet: 293T (human embryonic kidney cell line), NALM6 (pre-B-ALL cell line), CFPAC-1 (pancreatic ductal adenocarcinoma), CCRF-CEM (T-ALL) were obtained from the American Type Culture Collection (Rockville, MD), and BV173 (B-cell precursor leukemia) from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig, Germany).

Techniques: Expressing, Ex Vivo, Retroviral, Plasmid Preparation, Modification, In Vivo, Comparison

Journal: bioRxiv

Article Title: Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function

doi: 10.64898/2026.04.13.717612

Figure Lengend Snippet: a, Schematic of Fas88 receptor and expected downstream events. b, Schematic of γ-retroviral vector encoding Fas88. c, Representative overlay histogram of surface Fas expression in transduced (NGFR+) and untransduced (NGFR-) population in Fas88-modified Vδ2 T cells. d, Bar graph showing % apoptotic cells (Annexin V+ cells) upon exposure to soluble Fas ligand for 24 hrs (mean ± S.E. n=5). e, Line graph showing GFP induction in Jurkat-NFκB reporter cell line with either ΔFas or Fas88 modification upon exposure to soluble Fas ligand for 24 hrs at indicated concentration. (n=3, technical replicate). f, Expression of indicated proteins with or without exposure to soluble Fas ligand for 1 hr by Western blot. g, Results of 9-day coculture experiments against NALM6. Line graphs showing target cell fold change (left), CAR(+) cell fold change (middle) and %NGFR(+) cells (right) over time, and bar graphs showing Net area (baseline = 1) of tumor fold change (left) and CAR(+) fold change (right) from day 0 to day 9 (mean ± S.E. n=5). h,i, Results from in vivo experiments in NALM6 xenograft mouse model (n=6 in no treatment and 19BBz, n=5 in 19BBz+Fas88 and mbIL-18/19BBz+ΔFas). h, Tumor progression (top) and Vδ2 T cell expansion (bottom) in individual mice over time detected by either CBG bioluminescence or AkaLuc bioluminescence, respectively. i, Overall animal survival in each experimental group. j, Schematic of CFPAC-1 in vivo experiments (n=8 in tumor only, n=7 in NT, PBBz, PBBz+Fas88, and mbIL-18/PBBz+ΔFas). k, Line graphs showing tumor volume in each treatment group over time. l, Overall mouse survival in each experimental group. Statistical differences are calculated by Two-way ANOVA with Sidak’s multiple comparison (d), One-way ANOVA with Tukey’s multiple comparison (g), or the log-rank test (i,l). ✱✱ p ≤ 0.01, ✱✱✱ p ≤ 0.001, ✱✱✱✱ p ≤ 0.0001, ns; non-significant.

Article Snippet: 293T (human embryonic kidney cell line), NALM6 (pre-B-ALL cell line), CFPAC-1 (pancreatic ductal adenocarcinoma), CCRF-CEM (T-ALL) were obtained from the American Type Culture Collection (Rockville, MD), and BV173 (B-cell precursor leukemia) from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig, Germany).

Techniques: Retroviral, Plasmid Preparation, Expressing, Modification, Concentration Assay, Western Blot, In Vivo, Comparison